Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer

Vinodh R. Nannan Panday(Slotervaartziekenhuis), Jos H. Beijnen(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Francisca J Koopman, Hilde Rosing(The Netherlands Cancer Institute), W.W. ten Bokkel Huinink, M. J. X. Hillebrand(The Netherlands Cancer Institute), Jan HM Schellens(Slotervaartziekenhuis), R. Dubbelman(The Netherlands Cancer Institute)
Anti-Cancer Drugs
September 1, 1998
10.1097/00001813-199809000-00001
Cited by 8

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688